Sequana Medical Updates Stakeholder Transparency Notification

Transparency Notification from Shareholders

Transparency Notification from Shareholders

Ghent, Belgium - Sequana Medical NV (Euronext Brussels: SEQUA), a leader in treating drug-resistant fluid overload in liver disease, heart failure, and cancer, has announced a recent transparency notification regarding shareholder voting rights. The notification concerns the number of voting rights attributed to specific shares, as detailed below.

Notification Details

The notification reflects changes in the voting rights held by Société Fédérale de Participations et d'Investissement SA, along with its affiliated entities. The reason for this notification is the acquisition or transfer of voting securities, which has altered the number of voting rights held.

Voting Rights Breakdown

Aggregate number of shares and voting rights held: 3,285,134 shares, which accounts for 6.01% of the total outstanding shares. The total number of outstanding shares for the Company is 54,671,074, each conferring one voting right.

Significance of the Notification

On June 3, 2025, Belfius Insurance's holdings dropped below the 3% threshold, impacting the shareholdings of both Belfius Insurance and SFPI-FPIM, which jointly account for 6.01% of the total voting rights. This adjustment highlights the dynamic nature of share distributions and how they can influence corporate governance.

About Sequana Medical

Sequana Medical is revolutionizing treatment for fluid overload, which poses severe risks to patients with liver disease, heart failure, and cancer. Traditional diuretics often fail for these patients, necessitating innovative solutions like the alfapump® and DSR® systems. These therapies aim to alleviate the burdens associated with diuretic-resistant fluid overload, promising not just clinical improvements but also enhanced quality of life.

Recent Achievements and Future Plans

The Company received FDA approval for the alfapump System, marking a significant milestone in the treatment of recurrent ascites due to liver cirrhosis. With plans to launch in the United States by Q3 2025, Sequana Medical is poised to leverage a targeted specialty sales force to access key liver transplant centers.

Commitment to Effective Medical Solutions

Sequana Medical’s research, such as the promising results from the RED DESERT and SAHARA studies, continues to underline the efficacy of its treatments. These findings support DSR's potential in managing cardiorenal syndrome, showcasing the importance of their ongoing clinical trials.

Upcoming Initiatives

Sequana is dedicated to expanding its offerings in the field of fluid management therapies. Aiming to bridge the gap in effective treatment options, Sequana Medical is committed to continuous research and innovation in this vital health area.

Contact Information

For more information, please contact:

Sequana Medical

Investor relations
E: IR@sequanamedical.com
T: +32 9 292 8065

Frequently Asked Questions

What is the purpose of Sequana Medical's transparency notification?

The transparency notification informs stakeholders about changes in the voting rights related to specific shareholders, ensuring compliance with regulatory standards.

How many voting rights does the Société Fédérale de Participations et d'Investissement SA hold?

Société Fédérale de Participations et d'Investissement SA holds 3,285,134 voting rights, equivalent to 6.01% of the total outstanding shares.

What recent developments has Sequana Medical achieved?

Sequana Medical recently received FDA approval for its alfapump System for treating liver-related recurrent ascites, a significant advancement for the company.

When does Sequana Medical plan to commercialize the alfapump in the US?

The company plans to begin commercial operations for the alfapump System in the US by Q3 2025.

What innovations does Sequana Medical offer to patients?

Sequana Medical is focused on addressing fluid overload in patients with liver disease, heart failure, and cancer through innovative solutions like alfapump® and DSR® therapy, enhancing their quality of life.

About The Author

Greetings, I'm 32-year-old author and financial specialist Evelyn Baker. My introduction into the financial industry started with an economics degree and continued with a wealth of experience in wealth management and financial consulting. My great passion over the years has been assisting people and companies in making wise, well-informed decisions to reach their financial objectives.

My goal with writing is to simplify difficult financial ideas into understandable, doable guidance. My goal in writing many books and articles is to make personal finance understandable to everyone, irrespective of their experience or background. I want to give readers the information they need to take charge of their financial futures, from investing and retirement planning to budgeting and saving.

Along with my writing, I lead webinars and workshops where I provide doable advice and methods for achieving financial success. To reach a larger audience, I also frequently contribute to financial blogs and publications. My method is always to offer doable, real-world guidance that can actually improve people's lives.

Aside from my job, I like to cook, travel, and experience other cultures. I work hard to apply my belief in the value of a balanced life to my financial counsel. My goal in working is to encourage and enable people to succeed financially so they may lead the best lives possible.

Contact Evelyn Baker privately here. Or send an email with ATTN: Evelyn Baker as the subject to contact@investorshangout.com.

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.